Therapeutic strategies for uncomplicated cystitis in women.

Autor:	Naber KG; Department of Urology, Technical University of Munich, Germany., Alidjanov JF; Biostatistics & Data Science R&D, Bionorica SE, Neumarkt, Germany., Fünfstück R; Sophien- and Hufeland Hospital, Weimar, Germany., Strohmaier WL; Medical School Regiomed, Coburg, Germany.; Julius Maximilian University, Wuerzburg, Germany.; University of Split, Croatia., Kranz J; Department of Urology and Pediatric Urology, University Medical Center RWTH Aachen, Germany.; Department of Urology and Kidney Transplantation, Martin Luther University, Halle (Saale), Germany., Cai T; Department of Urology, Santa Chiara Regional Hospital, Trento, Italy., Pilatz A; Clinic for Urology, Pediatric Urology and Andrology, Justus Liebig University of Giessen, Germany., Wagenlehner FM; Clinic for Urology, Pediatric Urology and Andrology, Justus Liebig University of Giessen, Germany.
Jazyk:	angličtina
Zdroj:	GMS infectious diseases [GMS Infect Dis] 2024 Apr 29; Vol. 12, pp. Doc01. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024).
DOI:	10.3205/id000086
Abstrakt:	Uncomplicated cystitis is affecting many women of all ages and has a great impact on the quality of life, especially in women suffering from recurrent, uncomplicated cystitis. By far the most frequent uropathogen, E. coli , may have acquired increasing resistance against a variety of oral antibiotics, which may differ between countries and regions. Therefore, local resistance data are important to be considered. On the other hand, non-antibiotic therapy has also become an option which should be discussed and offered to the patient. In patients suffering from recurrent uncomplicated cystitis, individual risk factors and possible behavioral changes should first be taken into account. Non-antimicrobial prophylactic strategies shown to be successful in well-designed clinical studies are the next options. Long term antibiotic prophylaxis, however, should only be considered as a last option. For some of those patients self-diagnosis and self-treatment may be suitable, e.g. by using a recognized questionnaire. Competing Interests: KGN, JA, AP, and FMW are authors and copyright holders of the ACSS questionnaire. KGN is a consultant of Adamed Pharma, Bionorica, BioMerieux, GlaxoSmithKline, Immunotek, Ingenion Medical, Janssen Pharmaceutica, OM Pharma, and MIP Pharma. JA is an employee of Bionorica SE. WLS is a consultant of Bionorica, Desitin, MIP Pharma. JK is a consultant of Bionorica and GSK. FMW is a consultant of Achaogen, Astellas, AstraZeneca, Bionorica, MSD, Eumedica, GSK, Janssen, Klosterfrau, MIP Pharma, Pfizer, OM Pharma, Qiagen, VenatoRx. RF declares no conflict of interest. (Copyright © 2024 Naber et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu